Publication
Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors.
Authors not recorded
Endocr Relat Cancer2015PMID 25376618PMC4643672stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerNeuroendocrine Tumorcivic_curation1.00
- drugPasireotidecivic_curation1.00
- geneSSTR5civic_curation1.00
- variantSSTR5 Overexpressioncivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 25376618
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| SSTR5 Overexpression1 | ||||||||
| Pasireotide | Neuroendocrine Tumor | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID10193Phase II study of pasireotide in metastatic neuroendocrine tumours enrolled 29 patients. Overall median PFS was 11 months (95% CI, 7.6–16 months). High SSTR5 expression (seen in 17/22 samples measured… (full text at CIViC) PMID 25376618 · Cives et al., 2015 · Open in CIViC | civic |